Get informed when a big investor buys or sells
+ Follow-2.91
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Rallybio (RLYB) currently reports a PEG ratio of -2.91. That is above the Healthcare sector average of -6.46. Use the charts on this page to explore Rallybio's PEG ratio history and peer comparisons.
Rallybio's PEG ratio of -2.91 is higher than the Healthcare sector average of -6.46. That is roughly 54.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Rallybio's market price to a fundamental measure such as earnings, sales, or book value. At -2.91, RLYB can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of -2.91, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -6.46. From there, open related valuation or income-statement pages for Rallybio, and consider following RLYB for alerts when major investors trade the stock.
Rallybio is classified in the Healthcare sector. On PEG ratio, it currently shows -2.91 versus a sector average near -6.46. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RLYB with unrelated industries.